Silodosin NDC 27241-144

NDC codes

FDA NDC Directory

Product NDC (as listed)27241-144Labeler and product segments. Claims need a package NDC.

Product NDC at billing width27241-0144Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
27241-144-01	27241014401	30 CAPSULE in 1 BOTTLE (27241-144-01)Marketed from Dec 3, 2018

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Silodosin
Generic name (nonproprietary): silodosin
Active ingredients: Silodosin — 4 mg/1
Dosage form: Capsule
Route: Oral
Labeler: Ajanta Pharma USA Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 211060
Marketing start: Dec 3, 2018
Listing expires: Dec 31, 2026
Other FDA classes: Adrenergic alpha-Antagonists (Mechanism)
Identifiers: Product ID 27241-144_ae59631d-37e7-4fab-b160-fdfad41f6ce2SPL ID ae59631d-37e7-4fab-b160-fdfad41f6ce2SPL set ID e863be56-d303-43bb-915a-1b2568674e31RxCUI 809477, 826612UNII CUZ39LUY82UPC 0327241144011, 0327241145032, 0327241145018
Pharmacologic class: alpha-Adrenergic Blocker

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N427241014401 followed by a unit qualifier and the quantity

Package 27241-0144-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Nov 28, 2025.

Indications (excerpt from the label)

Silodosin capsules, a selective alpha-1 adrenergic receptor antagonist, is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) [see Clinical Studies ( 14 )]. Silodosin capsules are not indicated for the treatment of hypertension. Silodosin capsules, an alpha-1 adrenergic receptor antagonist, is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Silodosin is not indicated for the treatment of hypertension. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 211060

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 211060
Product	Strength	Form · route	Labeler	Product NDC
Silodosin	Silodosin 8 mg/1	CapsuleOral	Ajanta Pharma USA Inc.	27241-145